Hello Dr. ______
Our Annual Meeting date of November 5th has been confirmed. We continue to plan for that date.
Through Evercore, the Company is currently entertaining interested parties who would like to purchase the Animal Health business. We will be evaluating strategic alternatives for the business over the coming months leading up to the Annual Meeting. A shareholder vote will likely be required before the divestment can proceed.
Prior to the Annual Meeting, we will be presenting our case for consideration in an information circular to all shareholders. We expect the dissident shareholder group to do the same.
We have been engaging the dissident shareholders for some time now
It is clear that, with the benefit of the confidential information that they obtained, they have recognized the significance of corporate opportunities and the underlying value of the Company.
Bioniche is committed to maximizing shareholder value. As you know, the Board of Directors recently established a Special Committee of independent directors to oversee the strategic process to identify, examine, and consider many strategic opportunities that will achieve this goal, to the benefit of all shareholders.
GMP validation of the VMC is continuing and the targeted completion date remains this summer.
Sincerely,
Jennifer
Jennifer Shea
Vice-President, Communications, Investor & Government Relations
Bioniche Life Sciences Inc.
P.O. Box 1570, 231 Dundas St. E.
Belleville, Ontario
Canada K8N 5J2
Phone: 613-966-8058 ext. 1250
Mobile: 613-391-2097
Fax: 613-966-4177
Email: Jennifer.Shea@Bioniche.com